Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thromboprophylaxis and coagulation activation during neoadjuvant treatment for pancreatic cancer
2019-002496-33Phase 4Active
- Sponsor
- Helsinki University Hospital
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tinzaparin in pancreatic cancer (PC) (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Venous thrombotic events, Arterial thrombotic events and 3 more. Started Jan 2020; status: active.
02
Drugs
tinzaparin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-002496-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002496-33.